27Aug 2024
Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease

The study evaluated proptosis reduction from teprotumumab treatment as a percentage of pre-treatment proptosis. Among 119 patients, the reduction averaged 14.4% or 3.3 mm. Reporting as a percentage-based reduction offers better clinical insight into teprotumab's effectiveness.

  • #ophthalmology

Like

Save

Share